Marlborough, MA, United States
Marlborough, MA, United States

Time filter

Source Type

Patent
Sunovion Pharmaceuticals | Date: 2015-10-28

Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms thereof; a crystalline hydrochloride salt of transnorsertraline or a hydrate thereof; as well as the use of the pharmaceutical composition and the salt for the treatment of CNS diseases, including depression.


Patent
Sunovion Pharmaceuticals | Date: 2016-05-25

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising ()-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinsons disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.


Patent
Sunovion Pharmaceuticals | Date: 2016-01-20

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.


Patent
Sunovion Pharmaceuticals and PGi | Date: 2016-02-11

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R^(a), R^(1), R^(2), R^(3), R^(4), R^(6), w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.


Patent
Sunovion Pharmaceuticals | Date: 2016-01-22

Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.


Patent
Sunovion Pharmaceuticals | Date: 2016-02-02

Compounds that modulate GluR5 activity and methods of using the same are disclosed.


Patent
Sunovion Pharmaceuticals | Date: 2015-06-01

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.


Patent
Sunovion Pharmaceuticals | Date: 2015-09-10

Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.


Patent
Sunovion Pharmaceuticals | Date: 2015-05-18

This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.


Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A^(1), A^(2), R^(6), w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Loading Sunovion Pharmaceuticals collaborators
Loading Sunovion Pharmaceuticals collaborators